A Study of OnCARlytics (CF33-CD19) in Combination with Blinatumomab in Adults with Advanced or Metastatic Solid Tumors (OASIS)
- Conditions
- Solid Tumor, Adult
- Interventions
- First Posted Date
- 2023-10-02
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Imugene Limited
- Target Recruit Count
- 33
- Registration Number
- NCT06063317
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Emory Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸Northwestern, Chicago, Illinois, United States
A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors
- Conditions
- Solid TumorSolid CarcinomaSolid Tumor, AdultCholangiocarcinomaBile Duct CancerMetastatic CancerAdvanced Solid Tumor
- Interventions
- Biological: CF33-hNISBiological: Pembrolizumab
- First Posted Date
- 2022-04-26
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Imugene Limited
- Target Recruit Count
- 100
- Registration Number
- NCT05346484
- Locations
- 🇺🇸
University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸Highlands Oncology, Springdale, Arkansas, United States
🇺🇸City of Hope Medical Center, Duarte, California, United States
A Study of IMU-131 (HER-Vaxx) in Combination with Chemotherapy or Pembrolizumab in Patients with Metastatic HER2/neu Over-Expressing Gastric Cancer (nextHERIZON)
- Conditions
- Gastric CancerStomach AdenocarcinomaStomach CancerGastric AdenocarcinomaCancer of StomachGastroesophageal Junction Adenocarcinoma
- Interventions
- First Posted Date
- 2022-04-05
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Imugene Limited
- Target Recruit Count
- 7
- Registration Number
- NCT05311176
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
🇨🇳Kaohsiung Medical University Hospital, Kaohsiung City, Taiwan
🇨🇳National Cheng Kung University Hospital, Tainan City, Taiwan
A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults with Non-Small Cell Lung Cancer
- Conditions
- Non Small Cell Lung CancerNon Small Cell Lung Cancer Stage IIIBNon-small Cell Lung Cancer Stage IVLarge Cell Carcinoma LungSquamous Non-small-cell Lung CancerAdenocarcinoma Lung
- Interventions
- Biological: IMU-201 (administered as PD1-Vaxx) - Regimen 1Biological: IMU-201 (administered as PD1-Vaxx) - Regimen 2Biological: IMU-201 (administered as PD1-Vaxx) - Regimen 3Drug: AtezolizumabDrug: Standard of care chemotherapy
- First Posted Date
- 2020-06-16
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Imugene Limited
- Target Recruit Count
- 24
- Registration Number
- NCT04432207
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Mayo Clinic, Phoenix, Arizona, United States
🇦🇺Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia
Dose-escalation, Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Patients with R/r NHL and R/r B-cell ALL
- Conditions
- B-cell Acute Lymphoblastic LeukemiaNon-Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2018-09-11
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Imugene Limited
- Target Recruit Count
- 129
- Registration Number
- NCT03666000
- Locations
- 🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸City of Hope, Duarte, California, United States
🇺🇸H. Lee Moffitt Cancer Center, Tampa, Florida, United States
A Study of IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients with HER2 Positive Advanced Gastric Cancer
- Conditions
- Gastrointestinal NeoplasmsAdenocarcinoma
- Interventions
- First Posted Date
- 2016-06-10
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Imugene Limited
- Target Recruit Count
- 36
- Registration Number
- NCT02795988
- Locations
- 🇺🇦
ARENSIA Exploratory Medicine LLC, Kapitanivka, Ukraine
🇮🇳City Cancer Center, Vijayawada, Andhra Pradesh, India
🇮🇳North East Cancer Hospital and Research Institute, Guwahati, Assam, India